News Blast.
- Published in:
- Bio-IT World, 2005, v. 4, n. 10, p. 34
- Publication type:
- Article
Works matching DE "BAYER HealthCare AG"
Results: 36
1
2
News Blast.
- Published in:
- Bio-IT World, 2005, v. 4, n. 4, p. 12
- Publication type:
- Article
3
Bayer HealthCare launches Qlaira - The first estradiol-based oral contraceptive globally and now in South Africa.
- Published in:
- 2012
- Publication type:
- Product Review
4
Drug targets slip-sliding away.
- Published in:
- 2011
- Publication type:
- Editorial
5
Scientists Face the Cost of Irreproducible Results.
- Published in:
- Research Technology Management, 2016, v. 59, n. 1, p. 3
- By:
- Publication type:
- Article
6
Rewarding innovation in the animal health industry.
- Published in:
- Veterinary Record: Journal of the British Veterinary Association, 2006, v. 159, n. 20, p. 646, doi. 10.1136/vr.159.20.646-b
- Publication type:
- Article
7
Movers & Shakers.
- Published in:
- Chemistry & Industry, 2013, v. 77, n. 11, p. 40, doi. 10.1002/cind.7711_12.x
- Publication type:
- Article
8
Companies, technology & environment.
- Published in:
- Chemistry & Industry, 2011, n. 1, p. 13
- By:
- Publication type:
- Article
9
Science briefs.
- Published in:
- Chemistry & Industry, 2008, n. 7, p. 11
- Publication type:
- Article
10
Research briefs.
- Published in:
- Chemistry & Industry, 2007, n. 16, p. 8
- Publication type:
- Article
11
Research briefs.
- Published in:
- Chemistry & Industry, 2007, n. 14, p. 8
- Publication type:
- Article
12
News in brief.
- Published in:
- Chemistry & Industry, 2007, n. 5, p. 5
- Publication type:
- Article
13
800 jobs lost due to R&D consolidation.
- Published in:
- Chemistry & Industry, 2006, n. 23, p. 8
- By:
- Publication type:
- Article
14
Aflibercept Durability in Macular Diseases A focus on real-life evidence.
- Published in:
- 2015
- By:
- Publication type:
- Product Review
15
Vision Academy.
- Published in:
- Ophthalmology Times Europe, 2015, p. 1
- By:
- Publication type:
- Article
16
NICE recommends EYLEA® for visual impairment due to DMO.
- Published in:
- 2015
- Publication type:
- Product Review
17
CHALLENGING OUR TREATMENT APPROACH IN AMD.
- Published in:
- 2014
- By:
- Publication type:
- Proceeding
18
learnwithbayer.ca.
- Published in:
- Canadian Veterinary Journal / Revue Vétérinaire Canadienne, 2012, p. 7
- Publication type:
- Article
19
ZymoGenetics' moves recall young Genentech.
- Published in:
- Nature Biotechnology, 2007, v. 25, n. 9, p. 955, doi. 10.1038/nbt0907-955
- By:
- Publication type:
- Article
20
Grants4Targets: an open innovation initiative to foster drug discovery collaborations.
- Published in:
- Nature Reviews Drug Discovery, 2015, v. 14, n. 1, p. 74, doi. 10.1038/nrd3078-c2
- By:
- Publication type:
- Article
21
Short-Term Acetylsalicylic Acid (Aspirin) Use for Pain, Fever, or Colds - Gastrointestinal Adverse Effects.
- Published in:
- Drugs in R&D, 2011, v. 11, n. 3, p. 277, doi. 10.2165/11593880-000000000-00000
- By:
- Publication type:
- Article
22
Aflibercept: AVE 0005, AVE 005, AVE0005, VEGF Trap - Regeneron, VEGF Trap (R1R2), VEGF Trap-Eye.
- Published in:
- Drugs in R&D, 2008, v. 9, n. 4, p. 261
- Publication type:
- Article
23
Visanne®: dienogest.
- Published in:
- 2014
- Publication type:
- Product Review
24
SAAHIP exhibitors.
- Published in:
- South African Pharmaceutical Journal, 2012, v. 79, n. 4, p. 64
- Publication type:
- Article
25
Recommendations of the treat-and-extend regimen for neovascular age-related macular degeneration: 2020 updates.
- Published in:
- Hong Kong Journal of Ophthalmology, 2021, v. 25, n. 2, p. 39, doi. 10.12809/hkjo-v25n2-306
- By:
- Publication type:
- Article
26
Bayer HealthCare Delivers a Dose of Reality for Cloud Payoff Mantras in Multinationals.
- Published in:
- MIS Quarterly Executive, 2014, v. 13, n. 4, p. 193
- By:
- Publication type:
- Article
27
Feline Focus.
- Published in:
- Journal of Feline Medicine & Surgery, 2013, v. 15, n. 5, p. 425, doi. 10.1177/1098612X13486234
- Publication type:
- Article
28
The Efficacy of a Topically Applied Imidacloprid 10 % / Moxidectin 2.5 % Formulation (Advocate®, Advantage® Multi, Bayer) against Immature and Adult Spirocerca lupi Worms in Experimentally Infected Dogs.
- Published in:
- 2013
- By:
- Publication type:
- Abstract
29
Efficacy of Emodepside plus Toltrazuril Oral Suspension for Dogs (Procox, Bayer) against Trichuris vulpis in Naturally Infected Dogs.
- Published in:
- 2013
- By:
- Publication type:
- Abstract
30
Evaluation of the Efficacy of Imidacloprid 10 % / Moxidectin 2.5 % (Advocate, Advantage Multi, Bayer) for the Prevention of Dirofilaria repens Infection in Dogs.
- Published in:
- 2013
- By:
- Publication type:
- Abstract
31
Efficacy of Toltrazuril 5 % Suspension (Baycox, Bayer) and Diclazuril (Vecoxan, Janssen-Cilag) in the Control of Eimeria spp. in Lambs.
- Published in:
- 2013
- By:
- Publication type:
- Abstract
32
Fending Off Pirates.
- Published in:
- Financial Executive, 2008, v. 24, n. 2, p. 40
- By:
- Publication type:
- Article
33
The Political Economy of Family Planning: Population Dynamics and Contraceptive Markets.
- Published in:
- Development & Change, 2018, v. 49, n. 2, p. 259, doi. 10.1111/dech.12363
- By:
- Publication type:
- Article
34
Landes- und Bezirksverbände.
- Published in:
- Praktiker, 2019, v. 70, n. 7, p. 356
- Publication type:
- Article
35
PRODUCT NEWS.
- Published in:
- Australian Journal of Pharmacy, 2012, v. 93, n. 1106, p. 44
- Publication type:
- Article
36
Bayer case may set cost precedent.
- Published in:
- Journal of Intellectual Property Rights, 2012, v. 17, n. 2, p. 171
- Publication type:
- Article